Key result
Telmisartan 80 mg/day and losartan 50 mg/day both had a neutral effect on insulin resistance (HOMA-IR) after 8 weeks of treatment in hypertensive patients with metabolic syndrome.
Why the study?
Does telmisartan improve insulin resistance compared to losartan in hypertensive patients with metabolic syndrome?
RCT (n=42)
Randomized
No
Does telmisartan improve insulin resistance compared to losartan in hypertensive patients with metabolic syndrome?
Absolute Event Rate: 1.9% vs 1.8%
p-value: p=0.91
In hypertensive patients with metabolic syndrome, 8 weeks of telmisartan or losartan treatment effectively reduced blood pressure but had a neutral effect on insulin resistance.
No takes yet. Share an insight, caveat, or question.
Neither ARB improves insulin resistance; challenges hypothesized metabolic superiority of telmisartan in metabolic syndrome.
Bahadır et al. (2007) conducted an RCT in Hypertension with Metabolic Syndrome (n=42). Telmisartan vs. Losartan 50 mg/day was evaluated on Insulin resistance evaluated by HOMA-IR (p=0.91). Telmisartan 80 mg/day and losartan 50 mg/day both had a neutral effect on insulin resistance (HOMA-IR) after 8 weeks of treatment in hypertensive patients with metabolic syndrome.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: